Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study
- 714 Downloads
The ARCTIC study randomized 2440 patients scheduled for stent implantation to a strategy of platelet function monitoring with drug adjustment in patients who had a poor response to antiplatelet therapy or to a conventional strategy without monitoring and drug adjustment. No significant improvement in clinical outcomes with platelet function monitoring was observed.
The purpose of this study is to assess the relationships between CYP2C19 genotypes, clopidogrel pharmacodynamic response, and clinical outcome.
Methods and results
In the ARCTIC-GENE study, 1394 patients were genotyped for loss- and gain-of-function CYP2C19 alleles. Randomization of treatment strategy was well balanced. Slow metabolizers identified as carriers of at least one loss-of-function allele CYP2C19*2 (n = 459) were more likely poor responders at randomization (41.6 vs. 31.6 %, p = 0.0112) and 14 days later (23.8 vs. 10.4 %, p < 0.0001) and more frequently on prasugrel (11.5 vs. 8.1 %, p = 0.039) as compared with rapid metabolizers (n = 935). Intensification of antiplatelet treatment did not differ between slow and rapid metabolizers according to the study algorithm based on platelet function only. The primary study outcome defined as the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation did not differ between slow and rapid metabolizers (HR 0.988, 95 % CI [0.812;1.202], p = 0.90). Likewise, the primary safety outcome did not differ between rapid and slow metabolizer phenotype.
The genetic clopidogrel profile was a good marker of platelet function response on clopidogrel but was not related to clinical outcome suggesting that the genetic added little to the pharmacodynamic information used in the study to adjust antiplatelet therapy.
KeywordsAntiplatelet therapy Stent thrombosis Pharmacogenetic Platelet reactivity Clopidogrel
- 1.Authors/Task Force members, Windecker S, Kolh P, et al. (2014) 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541–2619CrossRefGoogle Scholar
- 9.Trenk D, Stone GW, Gawaz M, et al. (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59(24):2159–2164CrossRefPubMedGoogle Scholar
- 12.Aradi D, Storey RF, Komocsi A, et al. (2013) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 62(24):2261–2273Google Scholar
- 13.Collet JP, Cayla G, Cuisset T, et al. (2011) Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 161(1):5–12 e5CrossRefPubMedGoogle Scholar
- 18.http://www.fda.gov/Drugs/DrugSafety/Postmarket FDSC reduced effectiveness of P (clopidogrel) in patients who are poor metabolizers of the drug. A at:, DrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed April 28 2010. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug.
- 21.Frelinger 3rd AL, Bhatt DL, Lee RD, et al. (2013) Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61(8):872–879CrossRefPubMedGoogle Scholar
- 22.Price MJ, Murray SS, Angiolillo DJ, et al. (2012) Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59(22):1928–1937CrossRefPubMedGoogle Scholar
- 23.Fontana P, Cattaneo M, Combescure C, Reny J-L. Tailored thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc. 2013;2(2):e000131–e000131.Google Scholar
- 30.COLLET J, Kerneis M, Hulot JS, et al.; Point-of-care genetic profiling in acute coronary syndrome: the GAMMA Study. JESFC Paris 2015. Abstract 0466.Google Scholar